Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Tuberculosis: clinical trials on a newly developed drug initiated

06.06.2018

The first antibiotic against tuberculosis that has been developed in Germany is now ready for clinical testing. BTZ043, as the newly developed drug substance is called, is also effective against multidrug-resistant pathogens which are increasingly challenging successful treatment worldwide. Scientists from the Ludwig-Maximilians-Universität (LMU) Munich and the Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute (HKI) in Jena are leading this project. The German Center for Infection Research (DZIF) and the InfectControl 2020 consortium are funding a major part of the trials.

The problem of antibiotic resistance has increased sharply over the last decades. Today, we face the challenge of having to manage a growing number of multidrug-resistant pathogens against which only a few antibiotics have remained effective.


Tuberculosis bacteria: (left) treated with BTZ043, holes develop in the mycobacterial cell walls; (right) untreated

Dr Andreas Wieser

In the case of tuberculosis, the situation is particularly difficult as the treatment regimen still includes several antibiotics which need to be taken simultaneously. Additionally, mycobacteria, which cause tuberculosis, have many mechanisms with which they protect themselves against specific effects of different antibiotics. Consequently, several new agents, ideally with different modes of action, are urgently needed to develop new treatment forms.

New site on mycobacteria targeted

BTZ043 is the first member of a newly discovered class of antibiotics and chemically belongs to the benzothiazinones. “The agent irreversibly binds to an enzyme that is needed for bacterial cell wall synthesis,” explains Dr Florian Kloß, Head of the Transfer Group Antiinfectives of InfectControl 2020 at the HKI.

“As the enzyme can then no longer function, holes develop in the mycobacterial cell walls and the cell contents drain out,” adds DZIF scientist Prof Michael Hoelscher, Director of the Department of Infectious Diseases and Tropical Medicine at the LMU Munich (also see image). “The agent targets tuberculosis bacteria highly selectively and consequently does not affect other bacteria.”

Clinical trial tests tolerance

Recruitment of the first trial subjects for clinical testing of BTZ043 can now be initiated, following the approval of the Federal Institute for Drugs and Medical Devices (BfArM) and the Bavarian Chamber of Physicians’ Ethics Committee.

Led by Prof Hoelscher, up to 40 volunteers will receive the antibiotic at the trial centre of the company Nuvisan in Neu-Ulm. Hoelscher explains the procedure, “We want to ensure that the drug is absorbed by the body and is well-tolerated. To this end, a very low single dose will be administered, and subsequently this dose will gradually be increased for the next trial volunteers.” The aim of the trial is to reach the dose which showed good efficacy in animal models. This dose is far below the highest dose that the animals still tolerated well.

United against infections

A team of scientists and businessmen is involved in the development of this new tuberculosis drug. The agent, BTZ043, was discovered at the HKI in Jena. Since 2014, the drug has been developed further at the DZIF and InfectControl 2020 and other sites in a collaboration project between the Medical Center of the LMU Munich and the HKI.

The HKI is responsible for precise investigations of absorption, distribution, metabolism and excretion as well as for developing analytical methods for detecting metabolites. As a funder, the LMU Munich’s Medical Center is responsible for preclinical and clinical development as well as for quality and safety of the drug. The substance will be produced at Hapila GmbH, a medium-size pharmaceutical company in Gera.

Financing the drug development costs of several million euros has been made possible though joint public and private funding. Particularly the two research alliances DZIF and InfectControl 2020 are involved in developing the active agent. They are being funded by the Federal Ministry of Education and Research.

Contact

Prof Michael Hoelscher
Department of Infectious Diseases and Tropical Medicine at the Medical Center of LMU Munich
T +49 89 2180 17613
E-mail: hoelscher@lrz.uni-muenchen.de

DZIF Press Office
Karola Neubert and Janna Schmidt
T +49 531 6181 1170/1154
E-mail: presse@dzif.de

Karola Neubert | idw - Informationsdienst Wissenschaft
Further information:
http://www.dzif.de

More articles from Health and Medicine:

nachricht Study shows novel protein plays role in bacterial vaginosis
13.12.2019 | University of Arizona Health Sciences

nachricht Illinois team develops first of a kind in-vitro 3D neural tissue model
12.12.2019 | University of Illinois College of Engineering

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Virus multiplication in 3D

Vaccinia viruses serve as a vaccine against human smallpox and as the basis of new cancer therapies. Two studies now provide fascinating insights into their unusual propagation strategy at the atomic level.

For viruses to multiply, they usually need the support of the cells they infect. In many cases, only in their host’s nucleus can they find the machines,...

Im Focus: Cheers! Maxwell's electromagnetism extended to smaller scales

More than one hundred and fifty years have passed since the publication of James Clerk Maxwell's "A Dynamical Theory of the Electromagnetic Field" (1865). What would our lives be without this publication?

It is difficult to imagine, as this treatise revolutionized our fundamental understanding of electric fields, magnetic fields, and light. The twenty original...

Im Focus: Highly charged ion paves the way towards new physics

In a joint experimental and theoretical work performed at the Heidelberg Max Planck Institute for Nuclear Physics, an international team of physicists detected for the first time an orbital crossing in the highly charged ion Pr⁹⁺. Optical spectra were recorded employing an electron beam ion trap and analysed with the aid of atomic structure calculations. A proposed nHz-wide transition has been identified and its energy was determined with high precision. Theory predicts a very high sensitivity to new physics and extremely low susceptibility to external perturbations for this “clock line” making it a unique candidate for proposed precision studies.

Laser spectroscopy of neutral atoms and singly charged ions has reached astonishing precision by merit of a chain of technological advances during the past...

Im Focus: Ultrafast stimulated emission microscopy of single nanocrystals in Science

The ability to investigate the dynamics of single particle at the nano-scale and femtosecond level remained an unfathomed dream for years. It was not until the dawn of the 21st century that nanotechnology and femtoscience gradually merged together and the first ultrafast microscopy of individual quantum dots (QDs) and molecules was accomplished.

Ultrafast microscopy studies entirely rely on detecting nanoparticles or single molecules with luminescence techniques, which require efficient emitters to...

Im Focus: How to induce magnetism in graphene

Graphene, a two-dimensional structure made of carbon, is a material with excellent mechanical, electronic and optical properties. However, it did not seem suitable for magnetic applications. Together with international partners, Empa researchers have now succeeded in synthesizing a unique nanographene predicted in the 1970s, which conclusively demonstrates that carbon in very specific forms has magnetic properties that could permit future spintronic applications. The results have just been published in the renowned journal Nature Nanotechnology.

Depending on the shape and orientation of their edges, graphene nanostructures (also known as nanographenes) can have very different properties – for example,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

The Future of Work

03.12.2019 | Event News

First International Conference on Agrophotovoltaics in August 2020

15.11.2019 | Event News

Laser Symposium on Electromobility in Aachen: trends for the mobility revolution

15.11.2019 | Event News

 
Latest News

Supporting structures of wind turbines contribute to wind farm blockage effect

13.12.2019 | Physics and Astronomy

Chinese team makes nanoscopy breakthrough

13.12.2019 | Physics and Astronomy

Tiny quantum sensors watch materials transform under pressure

13.12.2019 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>